

# Cationic Chelation: A New Dynamic In Wound Care

Michael Lavor, MD; Jessica Barcelo, CCMA; Robert G. Frykberg, DPM, MPH

## BACKGROUND

81 year old female patient with multiple chronic non-healing wounds for 6+ years.

### PATIENT'S MEDICAL HISTORY

#### 2014

- Cancer of left breast, stage 1, estrogen receptor positive
- Acute CHF (congestive heart failure) possibly diastolic
- Mitral valve replacement 2014 and 2021

#### 2015

- Neuropathy, toxic (HCC)
- Osteoarthritis, localized, shoulder, right
- Hyperlipidemia

#### 2016

- Surgery right ankle fusion due to neuropathy
- Right ankle infection
- 3 Skin grafts lower extremity with later failure of grafts

#### 2017

- Split thickness graft right lower leg with later failure of grafts
- Congenital lymphedema

#### 2018

- PVD (peripheral vascular disease) (HCC)
- Atherosclerosis of native artery of both lower extremities with intermittent claudication (HCC)
- Varicose veins of left lower extremity with ulcer of ankle with fat layer exposed (HCC)

#### 2019

- Thigh shingles
- Bell's palsy

#### 2020

- Open wound of right knee with artificial knee with complication, subsequent encounter
- Popliteal artery stenosis, right (HCC)
- Tibial artery stenosis, right (HCC)

#### 2021

- Mitral valve replacement

#### 2022

- Acute respiratory failure with hypoxemia (HCC)
- Acute on chronic systolic CHF
- Acute PE
- Multiple open Wounds in bilateral low ext
- Moderate protein-calorie malnutrition (HCC)
- Hypercholesterolemia
- S/P MVR (mitral valve replacement)
- UTI (urinary tract infection)
- Sepsis (HCC)
- Pacemaker implanted

## CASE STUDY

### PATIENT ECONOMIC STUDY

BL was an 81-year-old patient with a history of severe comorbidities. At the time of treatment, she suffered from Acute Chronic Systolic CHF, Acute PE, Multiple open Wounds in bilateral low extremities, Moderate protein-calorie malnutrition (HCC), Hypercholesterolemia, S/P MVR (mitral valve replacement), UTI (urinary tract infection), Sepsis (HCC), Pacemaker implanted.29

Previous costs and treatments 2016 - July 2022 (5 years) have included:

1. Amniotic Tissue on at least three different occasions, totaling over \$200,000.
2. Dermal skin used on at least three occasions totaling at least \$80,000.
3. Hyperbaric chamber, Infliximab, Warton's jelly injections, accurate relief treatments over \$120,000.
4. Multiple operating room debridements cost over \$200,000.

Approximate total: \$800,000

New Treatment Protocol:

The patient was changed to

**BioRelease**

**Fentonite (AgFresh)**

The wounds were cleaned, and dressings were changed 3x a week.

Results After Three Months of Treatment/

1. Two wounds were entirely resolved.
2. Two wounds have been reduced by 60-70% in size, and healthy viable tissue can now be seen over the entire area of each wound.
3. The total product cost to date is around \$1,300.
4. Weekly office visits are \$7,500.
5. Treatment will continue to resolve the remaining wounds fully.

Approximate total: \$8,800

The original product treatment was 3.33x more expensive than the McCord System per month, and the McCord System healed 26x faster!

8/28/22




9/29/22



11/8/22



2/22/23



**INVESTIGATORS**  
**Michael Lavor, MD**  
 Medical Director of Saguaro Wound Care Clinic  
**Jessica Barcelo, CCMA**  
 Medical Assistant

**MCCORD**

**Robert G. Frykberg, DPM, MPH**  
 Medical Director McCord Research